Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:41:45.231Z.
Consensus retrieved: 2026-10-06T11:14:13.100Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:41:45.231Z.
Quote observation: 2026-10-06T14:40:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f97479f440d7a03605f533a56e26179237db48e588053495707f458dff3bcd44
Forward PE Ratio (N/A) = Dated Quote Price ($14.08) / Consensus Forward EPS ($-0.97)
FORWARD PE RATIO
N/A
Erasca, Inc.
Market Cap
$4.89B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Erasca, Inc. (ERAS) | $4.89B | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.83B | N/A |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.06B | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.73B | N/A |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.09B | 19.80 |
| Cogent Biosciences, Inc. (COGT)vs › | $5.09B | N/A |
| BillionToOne, Inc. (BLLN)vs › | $4.69B | 128.44 |
| LifeStance Health Group, Inc. (LFST)vs › | $4.64B | 74.48 |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.62B | N/A |
| CRISPR Therapeutics AG (CRSP)vs › | $5.24B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $14.08, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.97 | $-1.04 – $-0.94 | 7 | n/m |
| 2027-12-31 | $-0.62 | $-0.74 – $-0.55 | 7 | n/m |
| 2028-12-31 | $-0.78 | $-1.02 – $-0.60 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
